An Italian multicenter retrospective study of ceftolozane/tazobactam and ceftazidime/avibactam in children with hematologic malignancies and MDR Gram-negative bacteria infections
Latest Information Update: 17 Nov 2022
At a glance
- Drugs Avibactam/ceftazidime (Primary) ; Ceftolozane/tazobactam (Primary)
- Indications Gram-negative infections
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 01 Dec 2022 Results published in the Pediatric Infectious Disease Journal
- 17 Nov 2022 New trial record